-+ 0.00%
-+ 0.00%
-+ 0.00%

Calliditas Therapeutics Reports TRANSFORM Phase 2b Topline Data In Primary Biliary Cholangitis

Benzinga·07/26/2024 06:53:54
Listen to the news

alliditas Therapeutics AB (NASDAQ:CALT) (STOCKHOLM: CALTX) ("Calliditas") today announced that the Phase 2b TRANSFORM trial met its primary endpoint, showing statistically significant improvement in ALP (Alkaline Phosphatase) for both doses tested versus placebo. The trial evaluated setanaxib, a NOX enzyme inhibitor, in patients with primary biliary cholangitis (PBC) and elevated liver stiffness.